Five-years of treatment with belimumab, a BLyS-specific inhibitor, in patients with systemic Lupus Erythematosus (SLE): long-term safety and efficacy analyses

0145

  • Petri, M
  • Mccune, J
  • Wallace, D J
  • Merrill, J T
  • Furie, R A
  • Ginzler, E M
  • Stohl, W
  • Chatham, W
  • Weinstein, A
  • Pineda, L
  • Zhong, Z J
  • Klein, J
  • Hough, D
  • Freimuth, W

  • 1Johns Hopkins University, Baltimore, MD, United States

    2University of Michigan, Ann Arbor, MI, United States

    3Cedars-Sinai UCLA, West Hollywood, CA, United States

    4Oklahoma Medical Research Foundation, Oklahoma City, OK, United States

    5North Shore Long Island Jewish Health System, Lake Success, NY, United States

    6SUNY-Downstate, Brooklyn, NY, United States

    7University of Southern California, Los Angeles, CA, United States

    8University of Alabama-Birmingham, Birmingham, AL, United States

    9Washington Hospital Center, Washington, DC, United States

    10Human Genome Sciences, Inc., Rockville, MD, United States

International Journal of Rheumatic Diseases 13:p 110, July 2010.
Copyright © 2010 John Wiley & Sons, Inc.